In a groundbreaking multicenter French phase II study, researchers have taken a significant step forward in the fight against ovarian cancer by validating a novel homologous recombination deficiency (HRD) test known as GIScar (Genomic Instability Scar). This study, published in BMC Cancer, aims to enhance the precision of therapeutic strategies for high-grade serous ovarian cancer (HGSOC), a notoriously lethal form of the disease characterized by its responsiveness to specific treatments targeting DNA repair deficiencies.
Ovarian cancer remains one of the most challenging malignancies to treat, primarily due to its often late diagnosis and the genetic complexity underlying its pathology. Among the key mechanisms that influence therapeutic response is homologous recombination deficiency, a state where cells lose the ability to accurately repair double-strand DNA breaks. This immunocompromised repair pathway renders tumors exquisitely sensitive to platinum-based chemotherapies and PARP inhibitors such as olaparib, which exploit the tumor’s inability to mend DNA damage effectively.
Despite the clinical importance of identifying HRD tumors, the landscape of HRD testing is populated by numerous assays, many of which have yet to undergo rigorous prospective validation. This gap has hampered the widespread integration of HRD testing into routine practice. Addressing this need, the HERO trial launched an ambitious effort to prospectively validate the GIScar test across multiple French oncology centers, focusing on newly diagnosed HGSOC patients undergoing first-line platinum-based chemotherapy.
.adsslot_oh8b1Nxuv3{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_oh8b1Nxuv3{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_oh8b1Nxuv3{width:320px !important;height:50px !important;}
}
ADVERTISEMENT
The core of the HERO trial is to determine the predictive power of GIScar in identifying platinum-sensitive patients. Platinum sensitivity, in this context, is defined as the absence of disease progression within six months following the completion of first-line chemotherapy, according to the established RECIST 1.1 criteria. This endpoint offers a robust clinical correlate of therapeutic efficacy and sets the stage for personalized treatment planning based on molecular tumor profiling.
Integral to the study design is the comparative evaluation of GIScar alongside the commercially available MyChoice CDx assay developed by Myriad Genetics®. Both assays evaluate HRD status but differ in methodology and genomic targets. This head-to-head comparison aims to elucidate the concordance between the tests and the relative performance of the newly developed GIScar platform, which leverages next-generation sequencing (NGS) to detect genomic scars indicative of HRD.
The trial plans to enroll 88 patients, each subjected to both GIScar and MyChoice CDx analyses. Post molecular testing, patients will uniformly receive platinum-based chemotherapy, with or without bevacizumab, as dictated by the treating clinicians’ judgment and established guidelines. Subsequent maintenance therapy with olaparib—a PARP inhibitor—will be administered to patients demonstrating at least one positive HRD test, reflecting evolving clinical recommendations that prioritize targeted therapy for molecularly defined subgroups.
From a methodological standpoint, the GIScar assay represents a significant advancement in molecular diagnostics for ovarian cancer. Developed within an academic setting, this test is grounded in the detection of genomic instability patterns using NGS technology, aiming to provide a cost-effective and accessible alternative to proprietary commercial assays. If validated, GIScar has the potential to democratize HRD testing by facilitating broader access within public and private healthcare systems while maintaining high sensitivity and specificity.
Beyond the primary endpoint focusing on platinum sensitivity, the HERO trial incorporates critical secondary evaluations including overall survival and progression-free survival stratified by HRD status. Additionally, the study will monitor the kinetic changes in serum CA-125 levels via a kinetic elimination model (KELIM), a biomarker known to correlate with disease dynamics and treatment response in ovarian cancer. Such multifaceted analyses underscore the comprehensive nature of the trial’s design.
The implications of this study transcend the immediate context of ovarian cancer treatment. The integration of GIScar testing aligns with a larger paradigm shift in oncology that leverages genomic profiling to inform targeted therapy. This transition towards precision medicine heralds an era where treatments are increasingly tailored to the molecular underpinnings of individual tumors, maximizing efficacy and minimizing unnecessary toxicities.
Furthermore, the HERO trial exemplifies the critical role that academic and institutional research plays in complementing and challenging commercial diagnostic platforms. By advancing novel, cost-effective assays through rigorous clinical validation, the scientific community fosters competition and innovation, driving down costs and widening patient access to cutting-edge diagnostic tools.
Technical challenges inherent to HRD testing include the heterogeneity of tumor samples and the dynamic nature of genomic instability. The GIScar test employs intricate bioinformatic algorithms to quantify genomic scars, capturing a composite measure of DNA repair deficiency that extends beyond single gene mutations. This holistic view improves the sensitivity of detection, crucial for delineating true HRD-positive tumors that would benefit most from DNA repair targeting agents.
The HERO trial’s prospective nature marks a pivotal departure from retrospective analyses that have traditionally informed HRD test validation. Prospective validation offers heightened reliability by encompassing real-time clinical decision-making and outcomes, thus providing clinicians and regulatory agencies with robust evidence to endorse test use in standard care protocols.
As the trial is poised to continue follow-up for 48 months post-inclusion, the accrued data will provide longitudinal insights into the durability of treatment responses and long-term survival outcomes. These longitudinal analyses are critical in chronicling the impact of HRD-guided therapies on the natural history of ovarian cancer.
In an era where next-generation sequencing has revolutionized cancer genomics, the HERO study underscores the necessity of translating complex molecular data into clinically actionable formats. By refining the tools used to identify HRD, the study enhances oncologists’ armamentarium in the battle against ovarian cancer, promising personalized therapeutic routes with improved prognostic accuracy.
Going forward, wider adoption of validated HRD tests like GIScar could pave the way for a more nuanced understanding of tumor biology, fostering adaptive clinical trial designs that incorporate biomarker stratification. This approach not only heightens trial efficiency but accelerates the pace at which new targeted agents reach patients in need.
Ultimately, the HERO trial encapsulates the synergy between molecular innovation and clinical rigor. As the oncology field eagerly awaits the final results, the study portends a future where precision oncology is not a privilege but a standard, ensuring that ovarian cancer patients receive therapies explicitly tailored to the molecular vulnerabilities of their tumors.
The expanding repertoire of HRD assays, bolstered by studies such as HERO, is emblematic of the relentless pursuit to harness genomic information for improved patient outcomes. By grounding diagnostics in robust clinical evidence and technological innovation, the research community is charting a transformative course for cancer care.
Subject of Research: Homologous recombination deficiency (HRD) testing for therapeutic stratification in ovarian cancer.
Article Title: Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).
Article References:
Leman, R., Cherifi, F., Leheurteur, M. et al. Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).
BMC Cancer 25, 1075 (2025). https://doi.org/10.1186/s12885-025-14423-2
Image Credits: Scienmag.com
DOI: https://doi.org/10.1186/s12885-025-14423-2
Tags: advancements in genomic medicineDNA repair deficiency in tumorsGIScar test for HGSOChomologous recombination deficiency researchHRD testing in ovarian cancermulticenter clinical trials in Francenovel cancer therapies for ovarian cancerovercoming challenges in cancer diagnosisPARP inhibitors in cancer treatmentplatinum-based chemotherapy effectivenessprecision medicine in oncologyvalidation of cancer biomarkers
